Neurology

Protecting Your Future: Long-Term Stroke Prevention

At a Glance

After a cerebral infarction, preventing another stroke means using the medication matched to its cause, controlling blood pressure and bad cholesterol, and evaluating carotid narrowing when appropriate. Never change blood-thinning medicines without medical guidance.

After the immediate crisis of a stroke has passed, the focus shifts to secondary prevention—the lifelong work of preventing a second event. While risk can never be entirely eliminated, research shows that combining targeted medical treatments with lifestyle changes can substantially reduce your risk of a recurrent stroke ^[1]. This stage of your journey is about transforming your health from an emergency into a manageable plan.

Medication Safety Warning: Keep an up-to-date medication list. Never start, stop, or change the dose of an antiplatelet or anticoagulant on your own. Always ask your doctor or pharmacist before starting new supplements or over-the-counter NSAIDs (like ibuprofen), and learn which signs of bleeding require urgent care.

Targeted Antiplatelet Therapy

If your stroke was not caused by a heart rhythm issue (noncardioembolic), your doctor will likely prescribe antiplatelet medications. These keep the cells in your blood (platelets) from sticking together and forming new clots ^[2].

Short-Term DAPT: For selected patients with early minor strokes or high-risk TIAs, doctors often prescribe Dual Antiplatelet Therapy (DAPT)—usually aspirin combined with clopidogrel or ticagrelor ^[3]. Depending on your specific indication, this lasts for a specific duration—often 21 to 30 days, and sometimes up to 90 days in certain other situations.
Transitioning to Single Therapy: After this initial high-risk period, you will usually switch to a single antiplatelet for long-term use ^[4]. Continuing DAPT indefinitely without a specific indication is generally discouraged because it significantly increases your risk of major bleeding without providing extra protection ^[5]^[6].

Managing Atrial Fibrillation (AFib)

If your stroke was caused by atrial fibrillation (a type of irregular heartbeat), you will likely need an anticoagulant (a medication that targets a different part of the clotting process) ^[7]. The exact timing of when to start this medication is chosen by your doctor based on the size of your stroke and your bleeding risk.

DOACs: Medications like apixaban or rivaroxaban—known as Direct Oral Anticoagulants (DOACs)—are now generally preferred over warfarin for most patients with nonvalvular AFib. They are at least as effective as warfarin but carry a lower risk of bleeding inside the brain ^[8]^[9].
Warfarin: This remains the standard for patients with specific heart conditions, such as mechanical heart valves ^[10]^[11].

The “Treat to Target” Strategy

Preventing another stroke requires meeting specific goals for your cholesterol and blood pressure, though you must never change medications to chase a target without your clinician.

Cholesterol (LDL-C): For those with evidence of artery narrowing (atherosclerosis), the goal is often to lower your “bad” cholesterol (LDL-C) to below 70 mg/dL ^[12].
- High-Intensity Statins: These are the first line of defense ^[13].
- Adding On: If statins alone don’t reach the goal, your doctor may add ezetimibe or a PCSK9 inhibitor to drive levels down further ^[14]^[15].
Blood Pressure: Contemporary secondary-prevention guidance commonly aims for a blood pressure below 130/80 mmHg for most stroke survivors when tolerated ^[16]. However, this target must be individualized based on age, kidney disease, frailty, and dizziness ^[17].

Surgical Options for Carotid Blockage

If testing shows a significant blockage (often 70% or greater) in the extracranial carotid artery on the side of your neck matching your stroke, you may be considered for a procedure to restore blood flow ^[18]. This is not automatic; it depends on your anatomy, surgical risk, and life expectancy. Selected patients with 50-69% stenosis may also benefit.

Carotid Endarterectomy (CEA): Surgery to physically remove the plaque from the artery wall. It is often favored over stenting in older adults when feasible because of procedural stroke risks ^[19]^[20].
Carotid Artery Stenting (CAS): Placing a mesh tube (stent) into the artery to hold it open. It is an individualized alternative ^[21]^[22].

When indicated for symptomatic patients, these procedures are ideally considered within the first 14 days while the risk of recurrence is highest, but the decision is always carefully individualized ^[23]^[24].

Common questions in this guide

How can I reduce my risk of another stroke after a cerebral infarction?

Secondary prevention combines medication chosen for the cause of the stroke with control of blood pressure and cholesterol. Taking medicines as prescribed, checking blood pressure, avoiding smoking, and following an agreed diet and activity plan can help lower risk. Your clinician should tailor the plan to your health.

Which medicine is used after a stroke: an antiplatelet or an anticoagulant?

For a stroke not caused by atrial fibrillation or another heart-related clot source, an antiplatelet such as aspirin or clopidogrel is commonly used. When atrial fibrillation caused the stroke, an anticoagulant such as apixaban, rivaroxaban, or warfarin may be recommended, depending on the heart condition and bleeding risk. Never start, stop, or change either type without medical advice.

How long should I take two antiplatelet medicines after a minor stroke or TIA?

Selected people with an early minor stroke or high-risk TIA may take two antiplatelet medicines, often for 21 to 30 days. In certain situations, treatment may continue up to 90 days before changing to one antiplatelet medicine. The exact stop date depends on why it was prescribed, and taking both long term can raise major bleeding risk.

What blood pressure and cholesterol targets are common after stroke?

For many stroke survivors, a blood pressure below 130/80 mmHg is a common goal when it can be reached safely. If artery plaque or narrowing is present, the LDL, or “bad” cholesterol, goal is often below 70 mg/dL. Age, kidney disease, frailty, dizziness, and other health factors may change these targets, so your clinician should set them.

When might I need carotid artery surgery or a stent?

A procedure may be considered when testing finds substantial narrowing in the neck’s carotid artery on the side linked to the stroke, especially 70% or more; some people with 50% to 69% narrowing may also benefit. Carotid endarterectomy removes plaque, while stenting props the artery open. Anatomy, procedure risk, life expectancy, and timing—often within 14 days when indicated—guide the decision.

How can I reduce bleeding risk while taking stroke-prevention medicines?

Keep an up-to-date list of your medicines and ask a doctor or pharmacist before using ibuprofen or another NSAID, or starting a supplement. Report new or unusual bruising or bleeding from the gums or nose, and ask what warning signs require urgent care. Do not change the dose or stop an antiplatelet or anticoagulant on your own.

Curated prompts to bring to your next appointment.

1.What is my current LDL-C (bad cholesterol) level, and is it below the recommended 70 mg/dL target?
2.If I am on Dual Antiplatelet Therapy (DAPT), what is the exact date I should switch to just one medication?
3.What was the specific cause of my stroke—was it related to an irregular heart rhythm like AFib or narrowing in my arteries?
4.Based on my specific health profile, what is our target blood pressure goal?
5.If I have a blockage in my neck (carotid artery), am I a candidate for surgery (CEA) or a stent (CAS)?
6.How will we monitor for side effects or bleeding while I am on these new medications?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

Secondary stroke prevention combines medication selected for the stroke’s cause with blood pressure, cholesterol, and lifestyle management.
Noncardioembolic strokes are usually managed with antiplatelet medicines, while atrial-fibrillation-related strokes generally require an anticoagulant selected for the heart condition and bleeding risk.
Selected people with a minor stroke or high-risk TIA may use two antiplatelet medicines for 21 to 30 days, and sometimes up to 90 days, before switching to one.
A blood pressure below 130/80 mmHg is often targeted when tolerated, while LDL cholesterol below 70 mg/dL is commonly used for people with atherosclerosis.
Symptomatic carotid narrowing of 70% or more, and selected 50% to 69% narrowing, may warrant carotid endarterectomy or stenting after individualized evaluation.

References (24)

1
Participation by patients from low- and middle-income countries (LMICs) in trial evidence supporting secondary stroke prevention guideline recommendations.
Opare-Addo PA, Sarfo FS, Berchie PO, et al.
Journal of the neurological sciences 2023; (448()):120641 doi:10.1016/j.jns.2023.120641.
PMID: 37028264
2
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Moustafa B, Testai FD
Current neurology and neuroscience reports 2022; (22(11)):789-802 doi:10.1007/s11910-022-01237-z.
PMID: 36227497
3
Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke.
Xian Y, Xu H, Matsouaka R, et al.
JAMA network open 2022; (5(7)):e2224157 doi:10.1001/jamanetworkopen.2022.24157.
PMID: 35900761
4
Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack.
Brown DL, Levine DA, Albright K, et al.
Stroke 2021; (52(7)):e468-e479 doi:10.1161/STR.0000000000000377.
PMID: 34024115
5
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
Kheiri B, Osman M, Abdalla A, et al.
Journal of thrombosis and thrombolysis 2019; (47(2)):233-247 doi:10.1007/s11239-018-1786-z.
PMID: 30511260
6
Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials.
Kwok CS, Shoamanesh A, Copley HC, et al.
Stroke 2015; (46(4)):1014-23 doi:10.1161/STROKEAHA.114.008422.
PMID: 25721018
7
Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.
Klijn CJ, Paciaroni M, Berge E, et al.
European stroke journal 2019; (4(3)):198-223 doi:10.1177/2396987319841187.
PMID: 31984228
8
Direct Oral Anticoagulants after Ischemic Stroke: Which Patient? Which Drug? And How Early?
De Marchis GM
Hamostaseologie 2021; (41(1)):31-34 doi:10.1055/a-1329-2523.
PMID: 33588452
9
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
Carnicelli AP, Hong H, Connolly SJ, et al.
Circulation 2022; (145(4)):242-255 doi:10.1161/CIRCULATIONAHA.121.056355.
PMID: 34985309
10
Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.
Fanaroff AC, Ohman EM
Annual review of medicine 2019; (70()):61-75 doi:10.1146/annurev-med-042617-092334.
PMID: 30477393
11
How to define valvular atrial fibrillation?
Fauchier L, Philippart R, Clementy N, et al.
Archives of cardiovascular diseases 2015; (108(10)):530-9.
PMID: 26184867
12
Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke.
Amarenco P, Kim JS, Labreuche J, et al.
Stroke 2020; (51(4)):1231-1239 doi:10.1161/STROKEAHA.119.028718.
PMID: 32078484
13
The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke.
Tsankof A, Tziomalos K
Diseases (Basel, Switzerland) 2021; (10(1)) doi:10.3390/diseases10010003.
PMID: 35076490
14
Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?
Deshotels MR, Virani SS, Ballantyne CM
Current cardiology reports 2021; (23(9)):116 doi:10.1007/s11886-021-01545-9.
PMID: 34269897
15
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Giugliano RP, Pedersen TR, Saver JL, et al.
Stroke 2020; (51(5)):1546-1554 doi:10.1161/STROKEAHA.119.027759.
PMID: 32312223
16
Medical Management for Secondary Stroke Prevention.
Kim AS
Continuum (Minneapolis, Minn.) 2020; (26(2)):435-456 doi:10.1212/CON.0000000000000849.
PMID: 32224760
17
Intracranial Hemorrhage in the TST Trial.
Amarenco P, Kim JS, Labreuche J, et al.
Stroke 2022; (53(2)):457-462 doi:10.1161/STROKEAHA.121.035846.
PMID: 34963300
18
European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis.
Bonati LH, Kakkos S, Berkefeld J, et al.
European stroke journal 2021; (6(2)):I-XLVII doi:10.1177/23969873211012121.
PMID: 34414302
19
Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease.
AbuRahma AF, Avgerinos ED, Chang RW, et al.
Journal of vascular surgery 2022; (75(1S)):4S-22S doi:10.1016/j.jvs.2021.04.073.
PMID: 34153348
20
Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis.
Müller MD, Lyrer P, Brown MM, Bonati LH
The Cochrane database of systematic reviews 2020; (2()):CD000515 doi:10.1002/14651858.CD000515.pub5.
PMID: 32096559
21
Early Endarterectomy Carries a Lower Procedural Risk Than Early Stenting in Patients With Symptomatic Stenosis of the Internal Carotid Artery: Results From 4 Randomized Controlled Trials.
Rantner B, Kollerits B, Roubin GS, et al.
Stroke 2017; (48(6)):1580-1587 doi:10.1161/STROKEAHA.116.016233.
PMID: 28455318
22
Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data.
Brott TG, Calvet D, Howard G, et al.
The Lancet. Neurology 2019; (18(4)):348-356 doi:10.1016/S1474-4422(19)30028-6.
PMID: 30738706
23
Time is brain: an update.
Naylor AR
Expert review of cardiovascular therapy 2015; (13(10)):1111-26 doi:10.1586/14779072.2015.1088781.
PMID: 26401920
24
Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar.
Diener HC, Hankey GJ
Journal of the American College of Cardiology 2020; (75(15)):1804-1818 doi:10.1016/j.jacc.2019.12.072.
PMID: 32299593

This page is for informational purposes only and does not constitute medical advice. It explains secondary prevention after cerebral infarction; consult your clinician before changing medicines or acting on treatment goals.

Get notified when new evidence is published on cerebral infarction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents